Geron Gets Cleared for First Embryonic Stem-Cell Test

Geron Corp. said it was cleared by U.S. regulators to proceed with the first human test of an embryonic stem-cell therapy, aimed at patients with spinal-cord injuries. The shares rose 17 percent.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.